Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab

Official Title

Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab

Summary:

The purpose of this study is to continue to provide elotuzumab and/or other study drugs to subjects who have participated on a prior protocol investigating elotuzumab who are not able to receive commercial drug supply.

Trial Description

Primary Outcome:

  • The number of subjects who received at least one dose of elotuzumab or backbone therapy (other study drugs) will be collected.
Secondary Outcome:
  • All serious adverse events (SAEs) and adverse events (AEs) will be collected.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society